8213 results for "canc*"

in 26.64 milliseconds.

• Biopsy and resection samples of HCC and non-tumor tissue

  A total of 16 patients with primary liver cancer, who first underwent diagnostic biopsy and then surgical resection shortly afterwards (median 27 days) were included. Tumor and non-tumor biopsy and resection tissue were analyzed by RNA sequencing. Total RNA from frozen tumor- and non-tumor tissue from biopsy and resection specimens was extracted using the ZR-Duet DNA and RNA MiniPrep Plus kit (Zymo Research) according to the manufacturer’s instructions. Prior to extraction, frozen tissues were crushed in liquid nitrogen to facilitate lysis. Extracted RNA was quantified using the Qubit Fluorometer (Thermo Fisher Scientific). 200 ng total RNA was used for RNAseq library prep with the TruSeq Stranded Total RNA Library Prep Kit with Ribo-Zero Gold (Illumina) according to the manufacturer’s specifications. Paired-End sequencing was performed on a Novaseq 6000 (Illumina) with 51 cycles at the Genomics Facility Basel according to the manufacturer’s guidelines.

  Dataset EGAD50000002291

• Study cfDNA molecular profiling for finding cancer signal in high risk Breast Cancer patients

  Whole genome sequencing of the matching blood from high risk breast cancer patients

  Dataset EGAD50000002653

• Study cfDNA molecular profiling for finding cancer signal in high risk Breast Cancer patients

  cfmedip methylation profiling CM from plasma cfDNA of high risk breast cancer patients

  Dataset EGAD50000002654

• FGFR2b Project Biliary Tract Cancer RNA Sequencing Data

  FASTQ files of RNA Sequencing data for the FGFR2b project.

  Dataset EGAD50000002899

• Germline WES of serrated polyposis syndrome

  The serrated polyposis syndrome (SPS) is a disease with a mainly unknown inherited genetic basis characterized by the presence of multiple and/or large serrated polyps in the colon and a higher associated risk for colorectal cancer (CRC). The objective of the present study was to identify new SPS/CRC germline predisposition genes by using whole-exome sequencing in two affected SPS patients from the same family.

  Study EGAS50000000765

• SOLTI- Arianna trial

  The main hypothesis of the study is that enzalutamide induces a significant proliferative arrest in HR+/HER2-negative breast cancer falling into the PAM50 HER2-E subtype. Patient population included males or pre/post-menopausal women with advanced HR+/HER2- ABC resistant to endocrine therapy, received ENZ 160 mg/day until disease progression. Patients were assigned to different cohorts according to PAM50 intrinsic subtypes identified in the pre-treatment tumor biopsy: Cohort A included pts with HER2-E and Cohort B pts with Luminal A/B tumors. Centralized molecular assessment was done at pre-treatment and C1D15.

  Study EGAS50000001979

• Study cfDNA molecular profiling for finding cancer signal in high risk Breast Cancer patients

  EM-seq methylation profiling MC of plasma cfDNA of high risk breast cancer patients

  Dataset EGAD50000002655

• Study cfDNA molecular profiling for finding cancer signal in high risk Breast Cancer patients

  Plasma cfDNA WGS profiling of high risk breast cancer patients.

  Dataset EGAD50000002656

• IMMUcan BC2 cohort

  The goal of IMMUcan is to understand how the immune system interacts with tumors and how therapeutic interventions influence this interaction. This cohort includes patients with confirmed localized TNBC (stages I to III) treated with neo-adjuvant therapy Comprehensive profiling data are integrated with longitudinally collected clinical information. Cellular profiling of the same tumor samples was performed using multiplex immunofluorescence imaging, imaging mass cytometry, and H&E staining.

  Study EGAS50000001938

• Impact of Mutated CTCF DNA binding sites of Topologically associating domains on nearby Cancer Gene Regulation: A Multi-Omics Analysis

  Cutaneous squamous cell carcinoma (cSCC) is the most common lethal malignancy world-wide. Due in most part to the extremely high mutational burden (TMB) in cSCC, making sense of it’s non-coding and regulatory regional genomic variation has lagged that of other far less common cancers. This study presents the first investigation of mutations at CCCTC-binding factor binding sites (CTCFbs) of Topologically associating domains (TAD) across defined cSCC progression stages—primary non-metastatic (PNM), primary metastat-ic (PM), and lymph node metastasis (LNM).

  Study EGAS50000001686

• RNA-seq from ASCENT cohort

  Bulk RNA sequencing data generated from primary resected non-small cell lung cancer (NSCLC) tumour tissue collected through the ASCENT study.

  Study EGAS50000001969

• IMC-F106C-101 dose escalation

  Brenetafusp is an ImmTAC bispecific (PRAME×CD3) targeting the cancer testis antigen PRAME. In this phase 1 study (NCT04262466), 126 HLA-A*02:01+ patients with advanced solid tumors received weekly IV doses from 0.3-320 mcg. The primary objective was to identify the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D); additional objectives included pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity. Brenetafusp demonstrated manageable safety and preliminary efficacy in PRAME+ tumors. A phase 3 trial in metastatic cutaneous melanoma is ongoing

  Study EGAS50000001976

• RNA-seq for "A preinvasive regulatory T cell axis for lung cancer interception" paper

  Bulk RNA sequencing data generated from primary resected non-small cell lung cancer (NSCLC) tumour tissue collected through the ASCENT study (Analysis of Screen-Detected Lung Cancers’ Genomic Traits; NCT04204499). The dataset comprises tumour RNA-seq from 89 patients with CT screen-detected NSCLC, predominantly early-stage disease, including lung adenocarcinoma and lung squamous cell carcinoma. The RNA-seq data were used to characterise tumour-immune transcriptional programmes and were analysed alongside matched peripheral blood immune profiling and clinical follow-up data.

  Dataset EGAD50000002852

• LUAD RNAseq – LORD

  RNA-seq data from paired normal and adenocarcinoma lung samples obtained from 515 patients that underwent lung cancer surgery.

  Study EGAS50000001705

• LUAD RNAseq - LORD

  The Lung Oncology Research and Discovery (LORD) program is a multi-omics translational initiative aimed at advancing precision medicine in lung cancer. It builds on a lung tissue biobank and leverages biological samples collected from patients who underwent lung cancer surgery at the IUCPQ-UL (Quebec City, Canada). LORD is therefore a single-site, retrospective, case-only study. Genomic profiling of biobanked samples is ongoing, with samples being analyzed sequentially in phases defined by sample type and omic modality. For this dataset, we provide RNA-seq data from paired normal and adenocarcinoma lung samples obtained from 515 patients.

  Dataset EGAD50000002450

• IMMUcan SYNERGY BC1 cohort

  The goal of IMMUcan is to understand how the immune system interacts with tumors and how therapeutic interventions influence this interaction. This cohort includes patients with advanced or metastatic triple-negative breast cancer (TNBC) treated with first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab enrolled in the SYNERGY trial. Comprehensive profiling data are integrated with longitudinally collected clinical information. Cellular profiling of the same tumor samples was performed using multiplex immunofluorescence imaging, imaging mass cytometry, and H&E staining.

  Study EGAS50000002010

• MOSAIC Window Glioblastoma Data

  This dataset will include Spatial Transcriptomics, Single-Cell RNA-Seq, Bulk RNA-Seq, Clinical data, WES, and H&E data from 10 Glioblastoma (GBM) Cancer patients. Researchers from private or public institutions outside the MOSAIC Consortium will be able to apply to access this data and, pending approval, use the data for their research.

  Dataset EGAD50000001352

• Non-invasive anal (pre)cancer dataset

  Molecular analysis of DNA from human anal swabs offers a non-invasive method for anal cancer screening. Current guidelines recommend anal swab-based screening and highlight the need for objective biomarkers to improve risk stratification. We performed genome-wide methylation profiling on DNA from 86 anal swab samples, including 40 HSIL-AIN3 cases (high-grade squamous intraepithelial lesions), 39 controls (<=LSIL), and 7 anal cancer patients, using the 850K Infinium MethylationEPIC BeadChip (Illumina). From this analysis, we identified a three-gene methylation classifier that showed strong discriminatory performance in distinguishing HSIL-AIN3 and anal cancer from <=LSIL lesions and successfully identified all anal cancer cases when applied to an independent validation cohort.

  Dataset EGAD00010002832

• Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer

  Background: Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease in which molecular stratification is needed to improve clinical outcomes. The identification of predictive biomarkers can have a major impact on the care of these patients, but the availability of metastatic tissue samples for research in this setting is limited. Objective: To study the prevalence of immune biomarkers of potential clinical utility to immunotherapy in mCRPC by tumour RNA sequencing, and to determine their association with overall survival (OS).

  Study EGAS50000001269

• Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma - WGS validation cohort

  This reposiroty contains bulk WGS data generated by Blood Cancer Research Group (Ostrava, Czech Republic) as a part of publication named "Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma" published in Hemapshere.

  Study EGAS50000001211

• Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma - RNA validation cohort

  This reposiroty contains bulk RNA data generated by Blood Cancer Research Group (Ostrava, Czech Republic) as a part of publication named "Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma" published in Hemapshere.

  Study EGAS50000001212

• Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma - WGS

  This reposiroty contains bulk WGS data generated by Blood Cancer Research Group (Ostrava, Czech Republic) as a part of publication named "Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma" published in Hemapshere. The dataset contains 11 tumor-normal sample pairs.

  Dataset EGAD50000001724

• Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma - RNA

  This reposiroty contains bulk RNA data generated by Blood Cancer Research Group (Ostrava, Czech Republic) as a part of publication named "Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma" published in Hemapshere. The dataset contains RNAseq samples from bone marrows.

  Dataset EGAD50000001725

• Cancer Genomics Lab at Johns Hopkins

  Dac EGAC00001003656

• Pan Prostate Cancer Group Germany BAM files

  German early-onset prostate cancer whole-genome sequencing samples of the Pan-Prostate Cancer Genome (PPCG) project. Whole Genome Sequencing Illumina data from men with prostate cancer. Samples were taken from primary tissue obtained at prostatectomy with matched blood control.

  Dataset EGAD00001005997